Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial

INTRODUCTION: Non-alcoholic steatohepatitis (NASH) is now the commonest cause of chronic liver disease. Despite this, there are no universally accepted pharmacological therapies for NASH. Liraglutide (Victoza), a human glucagon-like peptide-1 (GLP-1) analogue, has been shown to improve weight loss,...

Descripción completa

Detalles Bibliográficos
Autores principales: Armstrong, Matthew J, Barton, Darren, Gaunt, Piers, Hull, Diana, Guo, Kathy, Stocken, Deborah, Gough, Stephen C L, Tomlinson, Jeremy W, Brown, Rachel M, Hübscher, Stefan G, Newsome, Philip N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2013
Materias:
Gastroenterology and Hepatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3822302/
https://www.ncbi.nlm.nih.gov/pubmed/24189085
http://dx.doi.org/10.1136/bmjopen-2013-003995

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3822302/
https://www.ncbi.nlm.nih.gov/pubmed/24189085
http://dx.doi.org/10.1136/bmjopen-2013-003995

Ejemplares similares